Axel S. Merseburger

Lübeck

Professor, Department of Urology and Editor-in-Chief at touchONCOLOGY

Featured in: Favicon

touchoncology.com Favicon

springer.com Favicon

thelancet.com Favicon

futuremedicine.com Favicon

cancernetwork.com Favicon

onclive.com Favicon

europeanurology.com Favicon

urotoday.com Favicon

urologytimes.com Favicon

link.springer.com

Articles

Real-World Data Support First-Line Avelumab Plus Axitinib in Advanced RCC

2 months ago | ajmc.com | Laura Joszt |Courtney Flaherty |Axel S. Merseburger

A real-world analysis of avelumab and axitinib to treat advanced renal cell carcinoma supports the frontline use of the combination and confirmed the findings of JAVELIN Renal 101 (NCT02684006), said Axel Merseburger, MD, professor of urology and chairman of the Department of Urology, University Hospital Schleswig Holstein, Campus Lübeck, and director of the Urologic Oncology Program, Hannover Medical School in Germany.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →